An expanded HIV care cascade: ART uptake, viral load suppression and comorbidity monitoring among adults living with HIV in Asia.


Journal

Antiviral therapy
ISSN: 2040-2058
Titre abrégé: Antivir Ther
Pays: England
ID NLM: 9815705

Informations de publication

Date de publication:
2020
Historique:
accepted: 06 01 2021
pubmed: 20 1 2021
medline: 26 10 2021
entrez: 19 1 2021
Statut: ppublish

Résumé

Comprehensive treatment and clinical management are central to improving outcomes for people living with HIV (PLHIV). We explored trends in HIV clinical care, treatment outcomes, and chronic kidney disease (CKD) and diabetes monitoring. We included patients ≥18 years in care at ten clinical sites in eight Asian countries. Proportions of patients on antiretroviral therapy (ART), with annual viral load, and with viral load suppression (VLS; <1,000 copies/ml) were estimated by year for 2011-2016, stratified by country income level (lower-middle income [LMIC] and high-income countries [HIC]). Among those on ART in 2016 we evaluated factors associated with annual CKD and diabetes monitoring. Among 31,346 patients (67% male), the proportions of patients on ART (median ART initiation year 2011, IQR 2007-2013), with annual viral load and VLS had substantially increased by 2016 (to 94%, 42% and 92%, respectively, in LMIC and 95%, 97% and 93%, respectively, in HIC) with the larger increases over time seen in LMIC. Among those on ART in 2016, monitoring proportions in LMIC were 53% for CKD and 26% for diabetes compared with 83% and 59%, respectively, in HIC. Overall, a decreased odds of monitoring was observed for male gender, heterosexual HIV exposure, no viral load and LMIC. Diabetes monitoring was also decreased in those with viral failure. Our findings highlight suboptimal monitoring of viral load, CKD and diabetes in PLHIV in Asia. There is a need for affordable and scalable monitoring options to improve the joint care for HIV and non-communicable diseases.

Sections du résumé

BACKGROUND
Comprehensive treatment and clinical management are central to improving outcomes for people living with HIV (PLHIV). We explored trends in HIV clinical care, treatment outcomes, and chronic kidney disease (CKD) and diabetes monitoring.
METHODS
We included patients ≥18 years in care at ten clinical sites in eight Asian countries. Proportions of patients on antiretroviral therapy (ART), with annual viral load, and with viral load suppression (VLS; <1,000 copies/ml) were estimated by year for 2011-2016, stratified by country income level (lower-middle income [LMIC] and high-income countries [HIC]). Among those on ART in 2016 we evaluated factors associated with annual CKD and diabetes monitoring.
RESULTS
Among 31,346 patients (67% male), the proportions of patients on ART (median ART initiation year 2011, IQR 2007-2013), with annual viral load and VLS had substantially increased by 2016 (to 94%, 42% and 92%, respectively, in LMIC and 95%, 97% and 93%, respectively, in HIC) with the larger increases over time seen in LMIC. Among those on ART in 2016, monitoring proportions in LMIC were 53% for CKD and 26% for diabetes compared with 83% and 59%, respectively, in HIC. Overall, a decreased odds of monitoring was observed for male gender, heterosexual HIV exposure, no viral load and LMIC. Diabetes monitoring was also decreased in those with viral failure.
CONCLUSIONS
Our findings highlight suboptimal monitoring of viral load, CKD and diabetes in PLHIV in Asia. There is a need for affordable and scalable monitoring options to improve the joint care for HIV and non-communicable diseases.

Identifiants

pubmed: 33464222
doi: 10.3851/IMP3379
pmc: PMC8272912
mid: NIHMS1721633
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

275-285

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI069907
Pays : United States

Références

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1996-2005
pubmed: 25035273
PLoS One. 2017 Nov 9;12(11):e0187591
pubmed: 29121661
AIDS. 2008 Nov 12;22(17):2291-302
pubmed: 18981768
Open Forum Infect Dis. 2018 Sep 05;5(10):ofy216
pubmed: 30320149
Drug Alcohol Depend. 2012 Jan 1;120(1-3):246-9
pubmed: 21831535
J Infect Chemother. 2018 Jul;24(7):549-554
pubmed: 29602711
PLoS One. 2018 Aug 10;13(8):e0197904
pubmed: 30096139
J Infect Dis. 2008 Apr 15;197(8):1145-55
pubmed: 18476293
Clin Diabetes. 2018 Jan;36(1):14-37
pubmed: 29382975
J Int Assoc Physicians AIDS Care (Chic). 2012 Nov-Dec;11(6):361-5
pubmed: 22745182
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S106-SS110
pubmed: 29514232
J Glob Health. 2019 Jun;9(1):010428
pubmed: 31293781
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
BMC Public Health. 2013 Aug 15;13:758
pubmed: 23947428
HIV Med. 2019 Oct;20(9):615-623
pubmed: 31338975
JMIR Public Health Surveill. 2018 Dec 20;4(4):e10989
pubmed: 30573446
Clin Infect Dis. 2016 Apr 15;62(8):1043-8
pubmed: 26743094
Lancet HIV. 2018 Aug;5(8):e438-e447
pubmed: 30025681
Lancet Infect Dis. 2009 Jul;9(7):409-17
pubmed: 19555900
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Kidney Int. 2015 Nov;88(5):950-7
pubmed: 26221752
BMC Med. 2016 Jun 22;14(1):94
pubmed: 27334606
Lancet Diabetes Endocrinol. 2020 Mar;8(3):239-248
pubmed: 31958403
Curr Opin Virol. 2016 Jun;18:50-6
pubmed: 27023283
J Clin Epidemiol. 2017 Jan;81:129-139
pubmed: 27771357
Diabetes Care. 2016 May;39(5):780-7
pubmed: 26965719
J Diabetes. 2019 Jul;11(7):522-539
pubmed: 30864190
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
PLoS One. 2017 Oct 23;12(10):e0186638
pubmed: 29059202
Clin Nephrol. 2015;83(7 Suppl 1):32-8
pubmed: 25725239
Int J Urol. 2011 Jan;18(1):32-42
pubmed: 20969645
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
Diabetes Metab Res Rev. 2017 Sep;33(6):
pubmed: 28437854
J Microbiol Immunol Infect. 2019 Oct;52(5):720-727
pubmed: 31358463
Clin Infect Dis. 2010 Sep 1;51(5):496-505
pubmed: 20673002
Lancet Infect Dis. 2018 Mar;18(3):e76-e86
pubmed: 29066132
BMJ Open. 2019 Dec 3;9(12):e032678
pubmed: 31796489
Liver Int. 2019 Oct;39(10):1868-1875
pubmed: 31136052
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):22024
pubmed: 28770588
J Microbiol Immunol Infect. 2015 Jun;48(3):256-62
pubmed: 24113068
J Int AIDS Soc. 2017 Nov;20 Suppl 7:
pubmed: 29171172
Vasc Med. 2018 Oct;23(5):476-477
pubmed: 30101683

Auteurs

Rimke Bijker (R)

The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.

Nagalingeswaran Kumarasamy (N)

Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS-Infectious Diseases Medical Centre, VHS, Chennai, India.

Sasisopin Kiertiburanakul (S)

Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Sanjay Pujari (S)

Institute of Infectious Diseases, Pune, India.

Oon Tek Ng (OT)

Department of Infectious Diseases, Tan Tock Seng Hospital, Novena, Singapore.

Ly Pehn Sun (LP)

National Center for HIV/AIDS, Dermatology & STDs, and University of Health Sciences, Phnom Penh, Cambodia.

Tuti Parwati Merati (TP)

Faculty of Medicine Udayana University & Sanglah Hospital, Bali, Indonesia.

Kinh Van Nguyen (K)

National Hospital for Tropical Diseases, Hanoi, Vietnam.

Man Po Lee (MP)

Queen Elizabeth Hospital, Kowloon, Hong Kong.

Do Duy Cuong (DD)

Bach Mai Hospital, Hanoi, Vietnam.

Yu Jiun Chan (YJ)

Taipei Veterans General Hospital, Taipei, Taiwan.

Jun Yong Choi (JY)

Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.

Jeremy Ross (J)

TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand.

Matthew Law (M)

The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH